In today’s dish, a clinical-stage biopharmaceutical company gets acquired for a fraction of its value less than a year after going public through a SPAC. Also, a paymen…
© 2024 Bill SPACman 📈
Substack is the home for great culture
In today’s dish, a clinical-stage biopharmaceutical company gets acquired for a fraction of its value less than a year after going public through a SPAC. Also, a paymen…